Answers are grounded in this paper and cite their sources.
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: